全文获取类型
收费全文 | 1965篇 |
免费 | 169篇 |
国内免费 | 3篇 |
专业分类
耳鼻咽喉 | 24篇 |
儿科学 | 25篇 |
妇产科学 | 28篇 |
基础医学 | 261篇 |
口腔科学 | 79篇 |
临床医学 | 198篇 |
内科学 | 323篇 |
皮肤病学 | 69篇 |
神经病学 | 182篇 |
特种医学 | 39篇 |
外科学 | 302篇 |
综合类 | 68篇 |
一般理论 | 1篇 |
预防医学 | 135篇 |
眼科学 | 134篇 |
药学 | 106篇 |
中国医学 | 3篇 |
肿瘤学 | 160篇 |
出版年
2023年 | 17篇 |
2022年 | 19篇 |
2021年 | 87篇 |
2020年 | 70篇 |
2019年 | 61篇 |
2018年 | 74篇 |
2017年 | 46篇 |
2016年 | 60篇 |
2015年 | 76篇 |
2014年 | 94篇 |
2013年 | 127篇 |
2012年 | 152篇 |
2011年 | 132篇 |
2010年 | 68篇 |
2009年 | 73篇 |
2008年 | 114篇 |
2007年 | 103篇 |
2006年 | 105篇 |
2005年 | 103篇 |
2004年 | 84篇 |
2003年 | 54篇 |
2002年 | 57篇 |
2001年 | 40篇 |
2000年 | 37篇 |
1999年 | 45篇 |
1998年 | 20篇 |
1997年 | 10篇 |
1996年 | 14篇 |
1995年 | 13篇 |
1994年 | 5篇 |
1992年 | 17篇 |
1991年 | 12篇 |
1990年 | 17篇 |
1989年 | 22篇 |
1988年 | 14篇 |
1987年 | 13篇 |
1986年 | 13篇 |
1985年 | 10篇 |
1984年 | 13篇 |
1983年 | 2篇 |
1982年 | 2篇 |
1981年 | 4篇 |
1979年 | 8篇 |
1978年 | 2篇 |
1977年 | 3篇 |
1976年 | 4篇 |
1974年 | 4篇 |
1973年 | 2篇 |
1969年 | 2篇 |
1968年 | 2篇 |
排序方式: 共有2137条查询结果,搜索用时 15 毫秒
21.
The results of the brain MRI procedures (n = 490) performed in a medium-sized community with a single MRI unit were reviewed. The non-neurologic medical practitioners ordered nearly as many brain scans as the neurospecialists (40.8% and 59.2% of the total scans respectively). The incidence of abnormal scans was 29.5% for the group of non-neurospecialists and 39.3% for the neurospecialists. A fairly large proportion (26.7%; n = 131) of the scans were requested to evaluate headaches. Twelve patients (9.2%) with headaches but without clear neurologic localizing features showed intracranial abnormalities in their MRI scans. Some of the abnormalities observed in the brain MRI scans could have been detected by a CT procedure. 相似文献
22.
23.
24.
25.
S Woudstra Z Bochdanovits M-J van Tol D J Veltman F G Zitman M A van Buchem N J van der Wee E M Opmeer L R Demenescu A Aleman B W Penninx W J Hoogendijk 《Translational psychiatry》2012,2(4):e99
Major depressive disorder (MDD) is characterized by affective symptoms and cognitive impairments, which have been associated with changes in limbic and prefrontal activity as well as with monoaminergic neurotransmission. A genome-wide association study implicated the polymorphism rs2522833 in the piccolo (PCLO) gene—involved in monoaminergic neurotransmission—as a risk factor for MDD. However, the role of the PCLO risk allele in emotion processing and executive function or its effect on their neural substrate has never been studied. We used functional magnetic resonance imaging (fMRI) to investigate PCLO risk allele carriers vs noncarriers during an emotional face processing task and a visuospatial planning task in 159 current MDD patients and healthy controls. In PCLO risk allele carriers, we found increased activity in the left amygdala during processing of angry and sad faces compared with noncarriers, independent of psychopathological status. During processing of fearful faces, the PCLO risk allele was associated with increased amygdala activation in MDD patients only. During the visuospatial planning task, we found no genotype effect on performance or on BOLD signal in our predefined areas as a function of increasing task load. The PCLO risk allele was found to be specifically associated with altered emotion processing, but not with executive dysfunction. Moreover, the PCLO risk allele appears to modulate amygdala function during fearful facial processing in MDD and may constitute a possible link between genotype and susceptibility for depression via altered processing of fearful stimuli. The current results may therefore aid in better understanding underlying neurobiological mechanisms in MDD. 相似文献
26.
27.
28.
Min‐Geol Lee Yu‐Huei Huang Joo‐Heung Lee Seung‐Chul Lee Tae‐Gyun Kim Derrick Chen‐Wee Aw Weibin Bao Cathleen Michelle A. Dee Adriana Guana Tsen‐Fang Tsai 《The Journal of dermatology》2019,46(9):752-758
The 52‐week results from the CLEAR (NCT02074982) study showed high and superior efficacy of secukinumab versus ustekinumab in clearing skin and improving patient‐reported outcomes, with comparable safety profile in subjects with moderate to severe psoriasis. Here, we analyzed the efficacy and safety of secukinumab in Asian subjects from the CLEAR study. In this double‐blind, phase IIIb study, eligible subjects with moderate to severe plaque psoriasis were randomized (1:1) to receive s.c. injection of secukinumab 300 mg or ustekinumab as per label. Of 62 subjects included in Asian subanalyses, 23 were randomized to secukinumab and 39 to ustekinumab. A significantly higher proportion of subjects achieved 90% or more improvement in Psoriasis Area and Severity Index (PASI 90) with secukinumab versus ustekinumab at week 16 (78.3% vs 35.9%, P = 0.0010) and at week 52 (60.9% vs 33.3%, P = 0.0196). Similarly, a higher proportion of subjects achieved PASI 100 with secukinumab versus ustekinumab at week 16 (43.5% vs 10.3%, P = 0.0029) and at week 52 (30.4% vs 12.8%, P = 0.0704). The median time to achieve 50% improvement in baseline PASI was 2.8 weeks in the secukinumab group versus 6.3 weeks in the ustekinumab group. The safety profile of secukinumab was in line with the known profile and no deaths occurred. Overall, 95.7% and 84.6% of subjects remained on secukinumab and ustekinumab, respectively. Similar to the core study, secukinumab showed sustained and superior efficacy with faster response versus ustekinumab, and no new or unexpected safety concerns were identified, in Asian subjects with moderate to severe plaque psoriasis. 相似文献
29.
30.